[A19-74] Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Adolescents and adults with inadequately controlled severe asthma with type 2 inflammation who are already receiving high-dose inhaled corticosteroids and at least 1 other medicinal product for maintenance treatment
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.